A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

  • Sarah A. Weiss
  • , Mario Sznol
  • , Montaser Shaheen
  • , Miguel Ángel Berciano-Guerrero
  • , Eva Muñoz Couselo
  • , Delvys Rodríguez-Abreu
  • , Valentina Boni
  • , Lynn M. Schuchter
  • , Maria Gonzalez-Cao
  • , Ana Arance
  • , Wei Wei
  • , Apar Kishor Ganti
  • , Ralph J. Hauke
  • , Alfonso Berrocal
  • , Nicholas O. Iannotti
  • , Frank J. Hsu
  • , Harriet M. Kluger

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science